JAGX:NASDAQJaguar Health, Inc. Analysis

Jaguar Health (JAGX) is trading well below its long‑term moving averages – the 20‑day SMA sits at 6.61 versus the current price of $3.70, while the 50‑day and 200‑day SMAs are 11.54 and 41.43 respectively, indicating a deep bearish bias. The RSI of 25 suggests the stock is oversold, and the MACD shows a modest bullish crossover (histogram +0.15), yet the overall trend remains bearish with a 30‑day volatility exceeding 240% and a beta of 3.2, reflecting extreme price swings. Fundamental metrics are stark: negative earnings (trailing EPS –$803.95), a max drawdown of -98.6%, and a balance sheet dominated by $43.6M of debt against under $1M cash, while the book value per share sits at –$99.20. Recent material news highlights a pending Nasdaq delisting decision and a reverse‑split approval, underscoring heightened listing risk, but the company also secured orphan‑drug designations for its short‑bowel syndrome program, offering a potential long‑run catalyst if clinical milestones are met.